Global Coagulation Factor IX (Human) Supply, Demand and Key Producers, 2026-2032
The global Coagulation Factor IX (Human) market size is expected to reach $ 460 million by 2032, rising at a market growth of 4.2% CAGR during the forecast period (2026-2032).
Coagulation Factor IX (Human) is a single-factor plasma-derived blood product manufactured by isolating and purifying factor IX from qualified human plasma, followed by validated viral inactivation or removal processes. It is generally supplied as a white or off-white lyophilized powder and reconstituted into a clear or slightly opalescent solution for intravenous infusion. The active ingredient is human coagulation factor IX, with stabilizers, buffer salts, and other formulation excipients as applicable, and potency is expressed in international units. The product belongs to plasma protein products, antihemorrhagic agents, and coagulation factor replacement therapies. Its key technical requirements include traceable plasma sourcing, protein purification, viral safety control, sterility assurance, lyophilized stability, potency testing, impurity control, and thrombogenicity-related quality control. Mechanistically, Coagulation Factor IX (Human) replaces deficient or missing factor IX in patients and, after activation within the coagulation cascade, participates in factor X activation, thrombin generation, and fibrin clot formation. It is mainly used for the treatment, prevention, and perioperative management of bleeding associated with hemophilia B or factor IX deficiency, subject to the approved label in each jurisdiction.
Market opportunities are mainly supported by the essential treatment needs of hemophilia B patients, improved access to rare disease medicines, broader reimbursement, hospital stockpiling demand, and better utilization of plasma fractions. Although Coagulation Factor IX (Human) serves a small patient population, acute bleeding control, perioperative hemostasis, and selected prophylaxis settings require reliable supply, giving the product resilient demand and strong clinical necessity. For plasma-product manufacturers, it improves the value extracted from coagulation-related plasma fractions and strengthens portfolio synergy with albumin, immunoglobulin, prothrombin complex concentrates, and other hemostatic products. Markets such as China still have room for better clinical access and domestic substitution.
The main challenges are constrained plasma supply, complex manufacturing, strict quality supervision, high batch-consistency requirements, and the direct impact of viral safety, sterility assurance, and thrombogenicity control on product approval and clinical confidence. The product is not being banned or phased out, but traditional plasma-derived preparations face substitution pressure in premium long-term prophylaxis markets. Recombinant factor products, extended half-life recombinant products, non-factor subcutaneous therapies, and gene therapies may divert some patients, especially in markets with strong reimbursement and mature home-treatment systems. As a result, Coagulation Factor IX (Human) will increasingly be positioned around supply security, emergency bleeding control, perioperative management, cost-sensitive markets, and selected replacement-therapy use cases.
Downstream demand is evolving from purely on-demand hemostasis toward a structure combining standardized diagnosis, hospital reserves, perioperative management, and selected long-term prophylaxis. Mature markets focus more on safety records, infusion convenience, real-world effectiveness, and the long-term value of alternative therapies, while emerging markets emphasize supply stability, reimbursement coverage, hospital procurement, and basic treatment availability. Future procurement will place greater weight on cost per unit of potency, batch quality stability, plasma-resource capability, viral safety systems, and continuous supply reliability. Overall, the product is unlikely to disappear quickly, but market growth will be steady rather than high-growth, with competition shifting toward quality, safety, price, and supply-chain strength.
This report studies the global Coagulation Factor IX (Human) production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Coagulation Factor IX (Human) and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Coagulation Factor IX (Human) that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Coagulation Factor IX (Human) total production and demand, 2021-2032, (K Pcs)
Global Coagulation Factor IX (Human) total production value, 2021-2032, (USD Million)
Global Coagulation Factor IX (Human) production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Pcs), (based on production site)
Global Coagulation Factor IX (Human) consumption by region & country, CAGR, 2021-2032 & (K Pcs)
U.S. VS China: Coagulation Factor IX (Human) domestic production, consumption, key domestic manufacturers and share
Global Coagulation Factor IX (Human) production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Pcs)
Global Coagulation Factor IX (Human) production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Pcs)
Global Coagulation Factor IX (Human) production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Pcs)
This report profiles key players in the global Coagulation Factor IX (Human) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CSL Behring, Takeda, Grifols Biologicals, Octapharma, Kedrion, Bio Products Laboratory, LFB, Biotest, KM Biologics, Intas Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Coagulation Factor IX (Human) market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Pcs) and average price (USD/Pcs) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Coagulation Factor IX (Human) Market, By Region:
1. How big is the global Coagulation Factor IX (Human) market?
2. What is the demand of the global Coagulation Factor IX (Human) market?
3. What is the year over year growth of the global Coagulation Factor IX (Human) market?
4. What is the production and production value of the global Coagulation Factor IX (Human) market?
5. Who are the key producers in the global Coagulation Factor IX (Human) market?
6. What are the growth factors driving the market demand?
Coagulation Factor IX (Human) is a single-factor plasma-derived blood product manufactured by isolating and purifying factor IX from qualified human plasma, followed by validated viral inactivation or removal processes. It is generally supplied as a white or off-white lyophilized powder and reconstituted into a clear or slightly opalescent solution for intravenous infusion. The active ingredient is human coagulation factor IX, with stabilizers, buffer salts, and other formulation excipients as applicable, and potency is expressed in international units. The product belongs to plasma protein products, antihemorrhagic agents, and coagulation factor replacement therapies. Its key technical requirements include traceable plasma sourcing, protein purification, viral safety control, sterility assurance, lyophilized stability, potency testing, impurity control, and thrombogenicity-related quality control. Mechanistically, Coagulation Factor IX (Human) replaces deficient or missing factor IX in patients and, after activation within the coagulation cascade, participates in factor X activation, thrombin generation, and fibrin clot formation. It is mainly used for the treatment, prevention, and perioperative management of bleeding associated with hemophilia B or factor IX deficiency, subject to the approved label in each jurisdiction.
Market opportunities are mainly supported by the essential treatment needs of hemophilia B patients, improved access to rare disease medicines, broader reimbursement, hospital stockpiling demand, and better utilization of plasma fractions. Although Coagulation Factor IX (Human) serves a small patient population, acute bleeding control, perioperative hemostasis, and selected prophylaxis settings require reliable supply, giving the product resilient demand and strong clinical necessity. For plasma-product manufacturers, it improves the value extracted from coagulation-related plasma fractions and strengthens portfolio synergy with albumin, immunoglobulin, prothrombin complex concentrates, and other hemostatic products. Markets such as China still have room for better clinical access and domestic substitution.
The main challenges are constrained plasma supply, complex manufacturing, strict quality supervision, high batch-consistency requirements, and the direct impact of viral safety, sterility assurance, and thrombogenicity control on product approval and clinical confidence. The product is not being banned or phased out, but traditional plasma-derived preparations face substitution pressure in premium long-term prophylaxis markets. Recombinant factor products, extended half-life recombinant products, non-factor subcutaneous therapies, and gene therapies may divert some patients, especially in markets with strong reimbursement and mature home-treatment systems. As a result, Coagulation Factor IX (Human) will increasingly be positioned around supply security, emergency bleeding control, perioperative management, cost-sensitive markets, and selected replacement-therapy use cases.
Downstream demand is evolving from purely on-demand hemostasis toward a structure combining standardized diagnosis, hospital reserves, perioperative management, and selected long-term prophylaxis. Mature markets focus more on safety records, infusion convenience, real-world effectiveness, and the long-term value of alternative therapies, while emerging markets emphasize supply stability, reimbursement coverage, hospital procurement, and basic treatment availability. Future procurement will place greater weight on cost per unit of potency, batch quality stability, plasma-resource capability, viral safety systems, and continuous supply reliability. Overall, the product is unlikely to disappear quickly, but market growth will be steady rather than high-growth, with competition shifting toward quality, safety, price, and supply-chain strength.
This report studies the global Coagulation Factor IX (Human) production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Coagulation Factor IX (Human) and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Coagulation Factor IX (Human) that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Coagulation Factor IX (Human) total production and demand, 2021-2032, (K Pcs)
Global Coagulation Factor IX (Human) total production value, 2021-2032, (USD Million)
Global Coagulation Factor IX (Human) production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Pcs), (based on production site)
Global Coagulation Factor IX (Human) consumption by region & country, CAGR, 2021-2032 & (K Pcs)
U.S. VS China: Coagulation Factor IX (Human) domestic production, consumption, key domestic manufacturers and share
Global Coagulation Factor IX (Human) production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Pcs)
Global Coagulation Factor IX (Human) production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Pcs)
Global Coagulation Factor IX (Human) production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Pcs)
This report profiles key players in the global Coagulation Factor IX (Human) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CSL Behring, Takeda, Grifols Biologicals, Octapharma, Kedrion, Bio Products Laboratory, LFB, Biotest, KM Biologics, Intas Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Coagulation Factor IX (Human) market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Pcs) and average price (USD/Pcs) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Coagulation Factor IX (Human) Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- High-Purity Coagulation Factor IX (Human)
- Intermediate-Purity Coagulation Factor IX (Human)
- Others
- Lyophilized Powder for Solution for Injection
- Liquid Solution for Injection
- Others
- 250 IU and Below
- Above 250 IU to 500 IU
- Above 500 IU to 1000 IU
- Above 1000 IU
- Solvent-Detergent Treated Products
- Virus-Filtered Products
- Heat-Treated or Pasteurized Products
- Multi-Step Viral Inactivation and Removal Products
- Hospital
- Personal Clinic
- Others
- CSL Behring
- Takeda
- Grifols Biologicals
- Octapharma
- Kedrion
- Bio Products Laboratory
- LFB
- Biotest
- KM Biologics
- Intas Pharmaceuticals
- Shandong Taibang Biological Products
- Sichuan Yuanda Shuyang Pharmaceutical
1. How big is the global Coagulation Factor IX (Human) market?
2. What is the demand of the global Coagulation Factor IX (Human) market?
3. What is the year over year growth of the global Coagulation Factor IX (Human) market?
4. What is the production and production value of the global Coagulation Factor IX (Human) market?
5. Who are the key producers in the global Coagulation Factor IX (Human) market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Coagulation Factor IX (Human) Introduction
1.2 World Coagulation Factor IX (Human) Supply & Forecast
1.2.1 World Coagulation Factor IX (Human) Production Value (2021 & 2025 & 2032)
1.2.2 World Coagulation Factor IX (Human) Production (2021-2032)
1.2.3 World Coagulation Factor IX (Human) Pricing Trends (2021-2032)
1.3 World Coagulation Factor IX (Human) Production by Region (Based on Production Site)
1.3.1 World Coagulation Factor IX (Human) Production Value by Region (2021-2032)
1.3.2 World Coagulation Factor IX (Human) Production by Region (2021-2032)
1.3.3 World Coagulation Factor IX (Human) Average Price by Region (2021-2032)
1.3.4 North America Coagulation Factor IX (Human) Production (2021-2032)
1.3.5 Europe Coagulation Factor IX (Human) Production (2021-2032)
1.3.6 China Coagulation Factor IX (Human) Production (2021-2032)
1.3.7 Japan Coagulation Factor IX (Human) Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Coagulation Factor IX (Human) Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Coagulation Factor IX (Human) Major Market Trends
2 DEMAND SUMMARY
2.1 World Coagulation Factor IX (Human) Demand (2021-2032)
2.2 World Coagulation Factor IX (Human) Consumption by Region
2.2.1 World Coagulation Factor IX (Human) Consumption by Region (2021-2026)
2.2.2 World Coagulation Factor IX (Human) Consumption Forecast by Region (2027-2032)
2.3 United States Coagulation Factor IX (Human) Consumption (2021-2032)
2.4 China Coagulation Factor IX (Human) Consumption (2021-2032)
2.5 Europe Coagulation Factor IX (Human) Consumption (2021-2032)
2.6 Japan Coagulation Factor IX (Human) Consumption (2021-2032)
2.7 South Korea Coagulation Factor IX (Human) Consumption (2021-2032)
2.8 ASEAN Coagulation Factor IX (Human) Consumption (2021-2032)
2.9 India Coagulation Factor IX (Human) Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Coagulation Factor IX (Human) Production Value by Manufacturer (2021-2026)
3.2 World Coagulation Factor IX (Human) Production by Manufacturer (2021-2026)
3.3 World Coagulation Factor IX (Human) Average Price by Manufacturer (2021-2026)
3.4 Coagulation Factor IX (Human) Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Coagulation Factor IX (Human) Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Coagulation Factor IX (Human) in 2025
3.5.3 Global Concentration Ratios (CR8) for Coagulation Factor IX (Human) in 2025
3.6 Coagulation Factor IX (Human) Market: Overall Company Footprint Analysis
3.6.1 Coagulation Factor IX (Human) Market: Region Footprint
3.6.2 Coagulation Factor IX (Human) Market: Company Product Type Footprint
3.6.3 Coagulation Factor IX (Human) Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Coagulation Factor IX (Human) Production Value Comparison
4.1.1 United States VS China: Coagulation Factor IX (Human) Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Coagulation Factor IX (Human) Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Coagulation Factor IX (Human) Production Comparison
4.2.1 United States VS China: Coagulation Factor IX (Human) Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Coagulation Factor IX (Human) Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Coagulation Factor IX (Human) Consumption Comparison
4.3.1 United States VS China: Coagulation Factor IX (Human) Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Coagulation Factor IX (Human) Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Coagulation Factor IX (Human) Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Coagulation Factor IX (Human) Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Coagulation Factor IX (Human) Production Value (2021-2026)
4.4.3 United States Based Manufacturers Coagulation Factor IX (Human) Production (2021-2026)
4.5 China Based Coagulation Factor IX (Human) Manufacturers and Market Share
4.5.1 China Based Coagulation Factor IX (Human) Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Coagulation Factor IX (Human) Production Value (2021-2026)
4.5.3 China Based Manufacturers Coagulation Factor IX (Human) Production (2021-2026)
4.6 Rest of World Based Coagulation Factor IX (Human) Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Coagulation Factor IX (Human) Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Coagulation Factor IX (Human) Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Coagulation Factor IX (Human) Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Coagulation Factor IX (Human) Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 High-Purity Coagulation Factor IX (Human)
5.2.2 Intermediate-Purity Coagulation Factor IX (Human)
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Coagulation Factor IX (Human) Production by Type (2021-2032)
5.3.2 World Coagulation Factor IX (Human) Production Value by Type (2021-2032)
5.3.3 World Coagulation Factor IX (Human) Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY DOSAGE FORM
6.1 World Coagulation Factor IX (Human) Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Dosage Form
6.2.1 Lyophilized Powder for Solution for Injection
6.2.2 Liquid Solution for Injection
6.2.3 Others
6.3 Market Segment by Dosage Form
6.3.1 World Coagulation Factor IX (Human) Production by Dosage Form (2021-2032)
6.3.2 World Coagulation Factor IX (Human) Production Value by Dosage Form (2021-2032)
6.3.3 World Coagulation Factor IX (Human) Average Price by Dosage Form (2021-2032)
7 MARKET ANALYSIS BY VIAL STRENGTH
7.1 World Coagulation Factor IX (Human) Market Size Overview by Vial Strength: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Vial Strength
7.2.1 250 IU and Below
7.2.2 Above 250 IU to 500 IU
7.2.3 Above 500 IU to 1000 IU
7.2.4 Above 1000 IU
7.3 Market Segment by Vial Strength
7.3.1 World Coagulation Factor IX (Human) Production by Vial Strength (2021-2032)
7.3.2 World Coagulation Factor IX (Human) Production Value by Vial Strength (2021-2032)
7.3.3 World Coagulation Factor IX (Human) Average Price by Vial Strength (2021-2032)
8 MARKET ANALYSIS BY VIRAL SAFETY PROCESSING ROUTE
8.1 World Coagulation Factor IX (Human) Market Size Overview by Viral Safety Processing Route: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Viral Safety Processing Route
8.2.1 Solvent-Detergent Treated Products
8.2.2 Virus-Filtered Products
8.2.3 Heat-Treated or Pasteurized Products
8.2.4 Multi-Step Viral Inactivation and Removal Products
8.3 Market Segment by Viral Safety Processing Route
8.3.1 World Coagulation Factor IX (Human) Production by Viral Safety Processing Route (2021-2032)
8.3.2 World Coagulation Factor IX (Human) Production Value by Viral Safety Processing Route (2021-2032)
8.3.3 World Coagulation Factor IX (Human) Average Price by Viral Safety Processing Route (2021-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Coagulation Factor IX (Human) Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Hospital
9.2.2 Personal Clinic
9.2.3 Others
9.3 Market Segment by Application
9.3.1 World Coagulation Factor IX (Human) Production by Application (2021-2032)
9.3.2 World Coagulation Factor IX (Human) Production Value by Application (2021-2032)
9.3.3 World Coagulation Factor IX (Human) Average Price by Application (2021-2032)
10 COMPANY PROFILES
10.1 CSL Behring
10.1.1 CSL Behring Details
10.1.2 CSL Behring Major Business
10.1.3 CSL Behring Coagulation Factor IX (Human) Product and Services
10.1.4 CSL Behring Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.1.5 CSL Behring Recent Developments/Updates
10.1.6 CSL Behring Competitive Strengths & Weaknesses
10.2 Takeda
10.2.1 Takeda Details
10.2.2 Takeda Major Business
10.2.3 Takeda Coagulation Factor IX (Human) Product and Services
10.2.4 Takeda Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.2.5 Takeda Recent Developments/Updates
10.2.6 Takeda Competitive Strengths & Weaknesses
10.3 Grifols Biologicals
10.3.1 Grifols Biologicals Details
10.3.2 Grifols Biologicals Major Business
10.3.3 Grifols Biologicals Coagulation Factor IX (Human) Product and Services
10.3.4 Grifols Biologicals Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.3.5 Grifols Biologicals Recent Developments/Updates
10.3.6 Grifols Biologicals Competitive Strengths & Weaknesses
10.4 Octapharma
10.4.1 Octapharma Details
10.4.2 Octapharma Major Business
10.4.3 Octapharma Coagulation Factor IX (Human) Product and Services
10.4.4 Octapharma Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.4.5 Octapharma Recent Developments/Updates
10.4.6 Octapharma Competitive Strengths & Weaknesses
10.5 Kedrion
10.5.1 Kedrion Details
10.5.2 Kedrion Major Business
10.5.3 Kedrion Coagulation Factor IX (Human) Product and Services
10.5.4 Kedrion Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.5.5 Kedrion Recent Developments/Updates
10.5.6 Kedrion Competitive Strengths & Weaknesses
10.6 Bio Products Laboratory
10.6.1 Bio Products Laboratory Details
10.6.2 Bio Products Laboratory Major Business
10.6.3 Bio Products Laboratory Coagulation Factor IX (Human) Product and Services
10.6.4 Bio Products Laboratory Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.6.5 Bio Products Laboratory Recent Developments/Updates
10.6.6 Bio Products Laboratory Competitive Strengths & Weaknesses
10.7 LFB
10.7.1 LFB Details
10.7.2 LFB Major Business
10.7.3 LFB Coagulation Factor IX (Human) Product and Services
10.7.4 LFB Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.7.5 LFB Recent Developments/Updates
10.7.6 LFB Competitive Strengths & Weaknesses
10.8 Biotest
10.8.1 Biotest Details
10.8.2 Biotest Major Business
10.8.3 Biotest Coagulation Factor IX (Human) Product and Services
10.8.4 Biotest Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.8.5 Biotest Recent Developments/Updates
10.8.6 Biotest Competitive Strengths & Weaknesses
10.9 KM Biologics
10.9.1 KM Biologics Details
10.9.2 KM Biologics Major Business
10.9.3 KM Biologics Coagulation Factor IX (Human) Product and Services
10.9.4 KM Biologics Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.9.5 KM Biologics Recent Developments/Updates
10.9.6 KM Biologics Competitive Strengths & Weaknesses
10.10 Intas Pharmaceuticals
10.10.1 Intas Pharmaceuticals Details
10.10.2 Intas Pharmaceuticals Major Business
10.10.3 Intas Pharmaceuticals Coagulation Factor IX (Human) Product and Services
10.10.4 Intas Pharmaceuticals Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.10.5 Intas Pharmaceuticals Recent Developments/Updates
10.10.6 Intas Pharmaceuticals Competitive Strengths & Weaknesses
10.11 Shandong Taibang Biological Products
10.11.1 Shandong Taibang Biological Products Details
10.11.2 Shandong Taibang Biological Products Major Business
10.11.3 Shandong Taibang Biological Products Coagulation Factor IX (Human) Product and Services
10.11.4 Shandong Taibang Biological Products Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.11.5 Shandong Taibang Biological Products Recent Developments/Updates
10.11.6 Shandong Taibang Biological Products Competitive Strengths & Weaknesses
10.12 Sichuan Yuanda Shuyang Pharmaceutical
10.12.1 Sichuan Yuanda Shuyang Pharmaceutical Details
10.12.2 Sichuan Yuanda Shuyang Pharmaceutical Major Business
10.12.3 Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Product and Services
10.12.4 Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.12.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Developments/Updates
10.12.6 Sichuan Yuanda Shuyang Pharmaceutical Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Coagulation Factor IX (Human) Industry Chain
11.2 Coagulation Factor IX (Human) Upstream Analysis
11.2.1 Coagulation Factor IX (Human) Core Raw Materials
11.2.2 Main Manufacturers of Coagulation Factor IX (Human) Core Raw Materials
11.3 Midstream Analysis
11.4 Downstream Analysis
11.5 Coagulation Factor IX (Human) Production Mode
11.6 Coagulation Factor IX (Human) Procurement Model
11.7 Coagulation Factor IX (Human) Industry Sales Model and Sales Channels
11.7.1 Coagulation Factor IX (Human) Sales Model
11.7.2 Coagulation Factor IX (Human) Typical Distributors
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
1.1 Coagulation Factor IX (Human) Introduction
1.2 World Coagulation Factor IX (Human) Supply & Forecast
1.2.1 World Coagulation Factor IX (Human) Production Value (2021 & 2025 & 2032)
1.2.2 World Coagulation Factor IX (Human) Production (2021-2032)
1.2.3 World Coagulation Factor IX (Human) Pricing Trends (2021-2032)
1.3 World Coagulation Factor IX (Human) Production by Region (Based on Production Site)
1.3.1 World Coagulation Factor IX (Human) Production Value by Region (2021-2032)
1.3.2 World Coagulation Factor IX (Human) Production by Region (2021-2032)
1.3.3 World Coagulation Factor IX (Human) Average Price by Region (2021-2032)
1.3.4 North America Coagulation Factor IX (Human) Production (2021-2032)
1.3.5 Europe Coagulation Factor IX (Human) Production (2021-2032)
1.3.6 China Coagulation Factor IX (Human) Production (2021-2032)
1.3.7 Japan Coagulation Factor IX (Human) Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Coagulation Factor IX (Human) Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Coagulation Factor IX (Human) Major Market Trends
2 DEMAND SUMMARY
2.1 World Coagulation Factor IX (Human) Demand (2021-2032)
2.2 World Coagulation Factor IX (Human) Consumption by Region
2.2.1 World Coagulation Factor IX (Human) Consumption by Region (2021-2026)
2.2.2 World Coagulation Factor IX (Human) Consumption Forecast by Region (2027-2032)
2.3 United States Coagulation Factor IX (Human) Consumption (2021-2032)
2.4 China Coagulation Factor IX (Human) Consumption (2021-2032)
2.5 Europe Coagulation Factor IX (Human) Consumption (2021-2032)
2.6 Japan Coagulation Factor IX (Human) Consumption (2021-2032)
2.7 South Korea Coagulation Factor IX (Human) Consumption (2021-2032)
2.8 ASEAN Coagulation Factor IX (Human) Consumption (2021-2032)
2.9 India Coagulation Factor IX (Human) Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Coagulation Factor IX (Human) Production Value by Manufacturer (2021-2026)
3.2 World Coagulation Factor IX (Human) Production by Manufacturer (2021-2026)
3.3 World Coagulation Factor IX (Human) Average Price by Manufacturer (2021-2026)
3.4 Coagulation Factor IX (Human) Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Coagulation Factor IX (Human) Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Coagulation Factor IX (Human) in 2025
3.5.3 Global Concentration Ratios (CR8) for Coagulation Factor IX (Human) in 2025
3.6 Coagulation Factor IX (Human) Market: Overall Company Footprint Analysis
3.6.1 Coagulation Factor IX (Human) Market: Region Footprint
3.6.2 Coagulation Factor IX (Human) Market: Company Product Type Footprint
3.6.3 Coagulation Factor IX (Human) Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Coagulation Factor IX (Human) Production Value Comparison
4.1.1 United States VS China: Coagulation Factor IX (Human) Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Coagulation Factor IX (Human) Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Coagulation Factor IX (Human) Production Comparison
4.2.1 United States VS China: Coagulation Factor IX (Human) Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Coagulation Factor IX (Human) Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Coagulation Factor IX (Human) Consumption Comparison
4.3.1 United States VS China: Coagulation Factor IX (Human) Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Coagulation Factor IX (Human) Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Coagulation Factor IX (Human) Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Coagulation Factor IX (Human) Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Coagulation Factor IX (Human) Production Value (2021-2026)
4.4.3 United States Based Manufacturers Coagulation Factor IX (Human) Production (2021-2026)
4.5 China Based Coagulation Factor IX (Human) Manufacturers and Market Share
4.5.1 China Based Coagulation Factor IX (Human) Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Coagulation Factor IX (Human) Production Value (2021-2026)
4.5.3 China Based Manufacturers Coagulation Factor IX (Human) Production (2021-2026)
4.6 Rest of World Based Coagulation Factor IX (Human) Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Coagulation Factor IX (Human) Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Coagulation Factor IX (Human) Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Coagulation Factor IX (Human) Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Coagulation Factor IX (Human) Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 High-Purity Coagulation Factor IX (Human)
5.2.2 Intermediate-Purity Coagulation Factor IX (Human)
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Coagulation Factor IX (Human) Production by Type (2021-2032)
5.3.2 World Coagulation Factor IX (Human) Production Value by Type (2021-2032)
5.3.3 World Coagulation Factor IX (Human) Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY DOSAGE FORM
6.1 World Coagulation Factor IX (Human) Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Dosage Form
6.2.1 Lyophilized Powder for Solution for Injection
6.2.2 Liquid Solution for Injection
6.2.3 Others
6.3 Market Segment by Dosage Form
6.3.1 World Coagulation Factor IX (Human) Production by Dosage Form (2021-2032)
6.3.2 World Coagulation Factor IX (Human) Production Value by Dosage Form (2021-2032)
6.3.3 World Coagulation Factor IX (Human) Average Price by Dosage Form (2021-2032)
7 MARKET ANALYSIS BY VIAL STRENGTH
7.1 World Coagulation Factor IX (Human) Market Size Overview by Vial Strength: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Vial Strength
7.2.1 250 IU and Below
7.2.2 Above 250 IU to 500 IU
7.2.3 Above 500 IU to 1000 IU
7.2.4 Above 1000 IU
7.3 Market Segment by Vial Strength
7.3.1 World Coagulation Factor IX (Human) Production by Vial Strength (2021-2032)
7.3.2 World Coagulation Factor IX (Human) Production Value by Vial Strength (2021-2032)
7.3.3 World Coagulation Factor IX (Human) Average Price by Vial Strength (2021-2032)
8 MARKET ANALYSIS BY VIRAL SAFETY PROCESSING ROUTE
8.1 World Coagulation Factor IX (Human) Market Size Overview by Viral Safety Processing Route: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Viral Safety Processing Route
8.2.1 Solvent-Detergent Treated Products
8.2.2 Virus-Filtered Products
8.2.3 Heat-Treated or Pasteurized Products
8.2.4 Multi-Step Viral Inactivation and Removal Products
8.3 Market Segment by Viral Safety Processing Route
8.3.1 World Coagulation Factor IX (Human) Production by Viral Safety Processing Route (2021-2032)
8.3.2 World Coagulation Factor IX (Human) Production Value by Viral Safety Processing Route (2021-2032)
8.3.3 World Coagulation Factor IX (Human) Average Price by Viral Safety Processing Route (2021-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Coagulation Factor IX (Human) Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Hospital
9.2.2 Personal Clinic
9.2.3 Others
9.3 Market Segment by Application
9.3.1 World Coagulation Factor IX (Human) Production by Application (2021-2032)
9.3.2 World Coagulation Factor IX (Human) Production Value by Application (2021-2032)
9.3.3 World Coagulation Factor IX (Human) Average Price by Application (2021-2032)
10 COMPANY PROFILES
10.1 CSL Behring
10.1.1 CSL Behring Details
10.1.2 CSL Behring Major Business
10.1.3 CSL Behring Coagulation Factor IX (Human) Product and Services
10.1.4 CSL Behring Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.1.5 CSL Behring Recent Developments/Updates
10.1.6 CSL Behring Competitive Strengths & Weaknesses
10.2 Takeda
10.2.1 Takeda Details
10.2.2 Takeda Major Business
10.2.3 Takeda Coagulation Factor IX (Human) Product and Services
10.2.4 Takeda Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.2.5 Takeda Recent Developments/Updates
10.2.6 Takeda Competitive Strengths & Weaknesses
10.3 Grifols Biologicals
10.3.1 Grifols Biologicals Details
10.3.2 Grifols Biologicals Major Business
10.3.3 Grifols Biologicals Coagulation Factor IX (Human) Product and Services
10.3.4 Grifols Biologicals Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.3.5 Grifols Biologicals Recent Developments/Updates
10.3.6 Grifols Biologicals Competitive Strengths & Weaknesses
10.4 Octapharma
10.4.1 Octapharma Details
10.4.2 Octapharma Major Business
10.4.3 Octapharma Coagulation Factor IX (Human) Product and Services
10.4.4 Octapharma Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.4.5 Octapharma Recent Developments/Updates
10.4.6 Octapharma Competitive Strengths & Weaknesses
10.5 Kedrion
10.5.1 Kedrion Details
10.5.2 Kedrion Major Business
10.5.3 Kedrion Coagulation Factor IX (Human) Product and Services
10.5.4 Kedrion Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.5.5 Kedrion Recent Developments/Updates
10.5.6 Kedrion Competitive Strengths & Weaknesses
10.6 Bio Products Laboratory
10.6.1 Bio Products Laboratory Details
10.6.2 Bio Products Laboratory Major Business
10.6.3 Bio Products Laboratory Coagulation Factor IX (Human) Product and Services
10.6.4 Bio Products Laboratory Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.6.5 Bio Products Laboratory Recent Developments/Updates
10.6.6 Bio Products Laboratory Competitive Strengths & Weaknesses
10.7 LFB
10.7.1 LFB Details
10.7.2 LFB Major Business
10.7.3 LFB Coagulation Factor IX (Human) Product and Services
10.7.4 LFB Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.7.5 LFB Recent Developments/Updates
10.7.6 LFB Competitive Strengths & Weaknesses
10.8 Biotest
10.8.1 Biotest Details
10.8.2 Biotest Major Business
10.8.3 Biotest Coagulation Factor IX (Human) Product and Services
10.8.4 Biotest Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.8.5 Biotest Recent Developments/Updates
10.8.6 Biotest Competitive Strengths & Weaknesses
10.9 KM Biologics
10.9.1 KM Biologics Details
10.9.2 KM Biologics Major Business
10.9.3 KM Biologics Coagulation Factor IX (Human) Product and Services
10.9.4 KM Biologics Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.9.5 KM Biologics Recent Developments/Updates
10.9.6 KM Biologics Competitive Strengths & Weaknesses
10.10 Intas Pharmaceuticals
10.10.1 Intas Pharmaceuticals Details
10.10.2 Intas Pharmaceuticals Major Business
10.10.3 Intas Pharmaceuticals Coagulation Factor IX (Human) Product and Services
10.10.4 Intas Pharmaceuticals Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.10.5 Intas Pharmaceuticals Recent Developments/Updates
10.10.6 Intas Pharmaceuticals Competitive Strengths & Weaknesses
10.11 Shandong Taibang Biological Products
10.11.1 Shandong Taibang Biological Products Details
10.11.2 Shandong Taibang Biological Products Major Business
10.11.3 Shandong Taibang Biological Products Coagulation Factor IX (Human) Product and Services
10.11.4 Shandong Taibang Biological Products Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.11.5 Shandong Taibang Biological Products Recent Developments/Updates
10.11.6 Shandong Taibang Biological Products Competitive Strengths & Weaknesses
10.12 Sichuan Yuanda Shuyang Pharmaceutical
10.12.1 Sichuan Yuanda Shuyang Pharmaceutical Details
10.12.2 Sichuan Yuanda Shuyang Pharmaceutical Major Business
10.12.3 Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Product and Services
10.12.4 Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.12.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Developments/Updates
10.12.6 Sichuan Yuanda Shuyang Pharmaceutical Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Coagulation Factor IX (Human) Industry Chain
11.2 Coagulation Factor IX (Human) Upstream Analysis
11.2.1 Coagulation Factor IX (Human) Core Raw Materials
11.2.2 Main Manufacturers of Coagulation Factor IX (Human) Core Raw Materials
11.3 Midstream Analysis
11.4 Downstream Analysis
11.5 Coagulation Factor IX (Human) Production Mode
11.6 Coagulation Factor IX (Human) Procurement Model
11.7 Coagulation Factor IX (Human) Industry Sales Model and Sales Channels
11.7.1 Coagulation Factor IX (Human) Sales Model
11.7.2 Coagulation Factor IX (Human) Typical Distributors
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
LIST OF TABLES
Table 1. World Coagulation Factor IX (Human) Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Coagulation Factor IX (Human) Production Value by Region (2021-2026) & (USD Million)
Table 3. World Coagulation Factor IX (Human) Production Value by Region (2027-2032) & (USD Million)
Table 4. World Coagulation Factor IX (Human) Production Value Market Share by Region (2021-2026)
Table 5. World Coagulation Factor IX (Human) Production Value Market Share by Region (2027-2032)
Table 6. World Coagulation Factor IX (Human) Production by Region (2021-2026) & (K Pcs)
Table 7. World Coagulation Factor IX (Human) Production by Region (2027-2032) & (K Pcs)
Table 8. World Coagulation Factor IX (Human) Production Market Share by Region (2021-2026)
Table 9. World Coagulation Factor IX (Human) Production Market Share by Region (2027-2032)
Table 10. World Coagulation Factor IX (Human) Average Price by Region (2021-2026) & (USD/Pcs)
Table 11. World Coagulation Factor IX (Human) Average Price by Region (2027-2032) & (USD/Pcs)
Table 12. Coagulation Factor IX (Human) Major Market Trends
Table 13. World Coagulation Factor IX (Human) Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Pcs)
Table 14. World Coagulation Factor IX (Human) Consumption by Region (2021-2026) & (K Pcs)
Table 15. World Coagulation Factor IX (Human) Consumption Forecast by Region (2027-2032) & (K Pcs)
Table 16. World Coagulation Factor IX (Human) Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Coagulation Factor IX (Human) Producers in 2025
Table 18. World Coagulation Factor IX (Human) Production by Manufacturer (2021-2026) & (K Pcs)
Table 19. Production Market Share of Key Coagulation Factor IX (Human) Producers in 2025
Table 20. World Coagulation Factor IX (Human) Average Price by Manufacturer (2021-2026) & (USD/Pcs)
Table 21. Global Coagulation Factor IX (Human) Company Evaluation Quadrant
Table 22. World Coagulation Factor IX (Human) Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Coagulation Factor IX (Human) Production Site of Key Manufacturer
Table 24. Coagulation Factor IX (Human) Market: Company Product Type Footprint
Table 25. Coagulation Factor IX (Human) Market: Company Product Application Footprint
Table 26. Coagulation Factor IX (Human) Competitive Factors
Table 27. Coagulation Factor IX (Human) New Entrant and Capacity Expansion Plans
Table 28. Coagulation Factor IX (Human) Mergers & Acquisitions Activity
Table 29. United States VS China Coagulation Factor IX (Human) Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Coagulation Factor IX (Human) Production Comparison, (2021 & 2025 & 2032) & (K Pcs)
Table 31. United States VS China Coagulation Factor IX (Human) Consumption Comparison, (2021 & 2025 & 2032) & (K Pcs)
Table 32. United States Based Coagulation Factor IX (Human) Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Coagulation Factor IX (Human) Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Coagulation Factor IX (Human) Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Coagulation Factor IX (Human) Production (2021-2026) & (K Pcs)
Table 36. United States Based Manufacturers Coagulation Factor IX (Human) Production Market Share (2021-2026)
Table 37. China Based Coagulation Factor IX (Human) Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Coagulation Factor IX (Human) Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Coagulation Factor IX (Human) Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Coagulation Factor IX (Human) Production, (2021-2026) & (K Pcs)
Table 41. China Based Manufacturers Coagulation Factor IX (Human) Production Market Share (2021-2026)
Table 42. Rest of World Based Coagulation Factor IX (Human) Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Coagulation Factor IX (Human) Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Coagulation Factor IX (Human) Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Coagulation Factor IX (Human) Production, (2021-2026) & (K Pcs)
Table 46. Rest of World Based Manufacturers Coagulation Factor IX (Human) Production Market Share (2021-2026)
Table 47. World Coagulation Factor IX (Human) Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Coagulation Factor IX (Human) Production by Type (2021-2026) & (K Pcs)
Table 49. World Coagulation Factor IX (Human) Production by Type (2027-2032) & (K Pcs)
Table 50. World Coagulation Factor IX (Human) Production Value by Type (2021-2026) & (USD Million)
Table 51. World Coagulation Factor IX (Human) Production Value by Type (2027-2032) & (USD Million)
Table 52. World Coagulation Factor IX (Human) Average Price by Type (2021-2026) & (USD/Pcs)
Table 53. World Coagulation Factor IX (Human) Average Price by Type (2027-2032) & (USD/Pcs)
Table 54. World Coagulation Factor IX (Human) Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 55. World Coagulation Factor IX (Human) Production by Dosage Form (2021-2026) & (K Pcs)
Table 56. World Coagulation Factor IX (Human) Production by Dosage Form (2027-2032) & (K Pcs)
Table 57. World Coagulation Factor IX (Human) Production Value by Dosage Form (2021-2026) & (USD Million)
Table 58. World Coagulation Factor IX (Human) Production Value by Dosage Form (2027-2032) & (USD Million)
Table 59. World Coagulation Factor IX (Human) Average Price by Dosage Form (2021-2026) & (USD/Pcs)
Table 60. World Coagulation Factor IX (Human) Average Price by Dosage Form (2027-2032) & (USD/Pcs)
Table 61. World Coagulation Factor IX (Human) Production Value by Vial Strength, (USD Million), 2021 & 2025 & 2032
Table 62. World Coagulation Factor IX (Human) Production by Vial Strength (2021-2026) & (K Pcs)
Table 63. World Coagulation Factor IX (Human) Production by Vial Strength (2027-2032) & (K Pcs)
Table 64. World Coagulation Factor IX (Human) Production Value by Vial Strength (2021-2026) & (USD Million)
Table 65. World Coagulation Factor IX (Human) Production Value by Vial Strength (2027-2032) & (USD Million)
Table 66. World Coagulation Factor IX (Human) Average Price by Vial Strength (2021-2026) & (USD/Pcs)
Table 67. World Coagulation Factor IX (Human) Average Price by Vial Strength (2027-2032) & (USD/Pcs)
Table 68. World Coagulation Factor IX (Human) Production Value by Viral Safety Processing Route, (USD Million), 2021 & 2025 & 2032
Table 69. World Coagulation Factor IX (Human) Production by Viral Safety Processing Route (2021-2026) & (K Pcs)
Table 70. World Coagulation Factor IX (Human) Production by Viral Safety Processing Route (2027-2032) & (K Pcs)
Table 71. World Coagulation Factor IX (Human) Production Value by Viral Safety Processing Route (2021-2026) & (USD Million)
Table 72. World Coagulation Factor IX (Human) Production Value by Viral Safety Processing Route (2027-2032) & (USD Million)
Table 73. World Coagulation Factor IX (Human) Average Price by Viral Safety Processing Route (2021-2026) & (USD/Pcs)
Table 74. World Coagulation Factor IX (Human) Average Price by Viral Safety Processing Route (2027-2032) & (USD/Pcs)
Table 75. World Coagulation Factor IX (Human) Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 76. World Coagulation Factor IX (Human) Production by Application (2021-2026) & (K Pcs)
Table 77. World Coagulation Factor IX (Human) Production by Application (2027-2032) & (K Pcs)
Table 78. World Coagulation Factor IX (Human) Production Value by Application (2021-2026) & (USD Million)
Table 79. World Coagulation Factor IX (Human) Production Value by Application (2027-2032) & (USD Million)
Table 80. World Coagulation Factor IX (Human) Average Price by Application (2021-2026) & (USD/Pcs)
Table 81. World Coagulation Factor IX (Human) Average Price by Application (2027-2032) & (USD/Pcs)
Table 82. CSL Behring Basic Information, Manufacturing Base and Competitors
Table 83. CSL Behring Major Business
Table 84. CSL Behring Coagulation Factor IX (Human) Product and Services
Table 85. CSL Behring Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 86. CSL Behring Recent Developments/Updates
Table 87. CSL Behring Competitive Strengths & Weaknesses
Table 88. Takeda Basic Information, Manufacturing Base and Competitors
Table 89. Takeda Major Business
Table 90. Takeda Coagulation Factor IX (Human) Product and Services
Table 91. Takeda Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 92. Takeda Recent Developments/Updates
Table 93. Takeda Competitive Strengths & Weaknesses
Table 94. Grifols Biologicals Basic Information, Manufacturing Base and Competitors
Table 95. Grifols Biologicals Major Business
Table 96. Grifols Biologicals Coagulation Factor IX (Human) Product and Services
Table 97. Grifols Biologicals Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 98. Grifols Biologicals Recent Developments/Updates
Table 99. Grifols Biologicals Competitive Strengths & Weaknesses
Table 100. Octapharma Basic Information, Manufacturing Base and Competitors
Table 101. Octapharma Major Business
Table 102. Octapharma Coagulation Factor IX (Human) Product and Services
Table 103. Octapharma Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 104. Octapharma Recent Developments/Updates
Table 105. Octapharma Competitive Strengths & Weaknesses
Table 106. Kedrion Basic Information, Manufacturing Base and Competitors
Table 107. Kedrion Major Business
Table 108. Kedrion Coagulation Factor IX (Human) Product and Services
Table 109. Kedrion Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Kedrion Recent Developments/Updates
Table 111. Kedrion Competitive Strengths & Weaknesses
Table 112. Bio Products Laboratory Basic Information, Manufacturing Base and Competitors
Table 113. Bio Products Laboratory Major Business
Table 114. Bio Products Laboratory Coagulation Factor IX (Human) Product and Services
Table 115. Bio Products Laboratory Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 116. Bio Products Laboratory Recent Developments/Updates
Table 117. Bio Products Laboratory Competitive Strengths & Weaknesses
Table 118. LFB Basic Information, Manufacturing Base and Competitors
Table 119. LFB Major Business
Table 120. LFB Coagulation Factor IX (Human) Product and Services
Table 121. LFB Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 122. LFB Recent Developments/Updates
Table 123. LFB Competitive Strengths & Weaknesses
Table 124. Biotest Basic Information, Manufacturing Base and Competitors
Table 125. Biotest Major Business
Table 126. Biotest Coagulation Factor IX (Human) Product and Services
Table 127. Biotest Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 128. Biotest Recent Developments/Updates
Table 129. Biotest Competitive Strengths & Weaknesses
Table 130. KM Biologics Basic Information, Manufacturing Base and Competitors
Table 131. KM Biologics Major Business
Table 132. KM Biologics Coagulation Factor IX (Human) Product and Services
Table 133. KM Biologics Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 134. KM Biologics Recent Developments/Updates
Table 135. KM Biologics Competitive Strengths & Weaknesses
Table 136. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 137. Intas Pharmaceuticals Major Business
Table 138. Intas Pharmaceuticals Coagulation Factor IX (Human) Product and Services
Table 139. Intas Pharmaceuticals Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 140. Intas Pharmaceuticals Recent Developments/Updates
Table 141. Intas Pharmaceuticals Competitive Strengths & Weaknesses
Table 142. Shandong Taibang Biological Products Basic Information, Manufacturing Base and Competitors
Table 143. Shandong Taibang Biological Products Major Business
Table 144. Shandong Taibang Biological Products Coagulation Factor IX (Human) Product and Services
Table 145. Shandong Taibang Biological Products Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 146. Shandong Taibang Biological Products Recent Developments/Updates
Table 147. Shandong Taibang Biological Products Competitive Strengths & Weaknesses
Table 148. Sichuan Yuanda Shuyang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 149. Sichuan Yuanda Shuyang Pharmaceutical Major Business
Table 150. Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Product and Services
Table 151. Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 152. Sichuan Yuanda Shuyang Pharmaceutical Recent Developments/Updates
Table 153. Sichuan Yuanda Shuyang Pharmaceutical Competitive Strengths & Weaknesses
Table 154. Global Key Players of Coagulation Factor IX (Human) Upstream (Raw Materials)
Table 155. Global Coagulation Factor IX (Human) Typical Customers
Table 156. Coagulation Factor IX (Human) Typical Distributors
Table 1. World Coagulation Factor IX (Human) Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Coagulation Factor IX (Human) Production Value by Region (2021-2026) & (USD Million)
Table 3. World Coagulation Factor IX (Human) Production Value by Region (2027-2032) & (USD Million)
Table 4. World Coagulation Factor IX (Human) Production Value Market Share by Region (2021-2026)
Table 5. World Coagulation Factor IX (Human) Production Value Market Share by Region (2027-2032)
Table 6. World Coagulation Factor IX (Human) Production by Region (2021-2026) & (K Pcs)
Table 7. World Coagulation Factor IX (Human) Production by Region (2027-2032) & (K Pcs)
Table 8. World Coagulation Factor IX (Human) Production Market Share by Region (2021-2026)
Table 9. World Coagulation Factor IX (Human) Production Market Share by Region (2027-2032)
Table 10. World Coagulation Factor IX (Human) Average Price by Region (2021-2026) & (USD/Pcs)
Table 11. World Coagulation Factor IX (Human) Average Price by Region (2027-2032) & (USD/Pcs)
Table 12. Coagulation Factor IX (Human) Major Market Trends
Table 13. World Coagulation Factor IX (Human) Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Pcs)
Table 14. World Coagulation Factor IX (Human) Consumption by Region (2021-2026) & (K Pcs)
Table 15. World Coagulation Factor IX (Human) Consumption Forecast by Region (2027-2032) & (K Pcs)
Table 16. World Coagulation Factor IX (Human) Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Coagulation Factor IX (Human) Producers in 2025
Table 18. World Coagulation Factor IX (Human) Production by Manufacturer (2021-2026) & (K Pcs)
Table 19. Production Market Share of Key Coagulation Factor IX (Human) Producers in 2025
Table 20. World Coagulation Factor IX (Human) Average Price by Manufacturer (2021-2026) & (USD/Pcs)
Table 21. Global Coagulation Factor IX (Human) Company Evaluation Quadrant
Table 22. World Coagulation Factor IX (Human) Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Coagulation Factor IX (Human) Production Site of Key Manufacturer
Table 24. Coagulation Factor IX (Human) Market: Company Product Type Footprint
Table 25. Coagulation Factor IX (Human) Market: Company Product Application Footprint
Table 26. Coagulation Factor IX (Human) Competitive Factors
Table 27. Coagulation Factor IX (Human) New Entrant and Capacity Expansion Plans
Table 28. Coagulation Factor IX (Human) Mergers & Acquisitions Activity
Table 29. United States VS China Coagulation Factor IX (Human) Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Coagulation Factor IX (Human) Production Comparison, (2021 & 2025 & 2032) & (K Pcs)
Table 31. United States VS China Coagulation Factor IX (Human) Consumption Comparison, (2021 & 2025 & 2032) & (K Pcs)
Table 32. United States Based Coagulation Factor IX (Human) Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Coagulation Factor IX (Human) Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Coagulation Factor IX (Human) Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Coagulation Factor IX (Human) Production (2021-2026) & (K Pcs)
Table 36. United States Based Manufacturers Coagulation Factor IX (Human) Production Market Share (2021-2026)
Table 37. China Based Coagulation Factor IX (Human) Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Coagulation Factor IX (Human) Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Coagulation Factor IX (Human) Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Coagulation Factor IX (Human) Production, (2021-2026) & (K Pcs)
Table 41. China Based Manufacturers Coagulation Factor IX (Human) Production Market Share (2021-2026)
Table 42. Rest of World Based Coagulation Factor IX (Human) Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Coagulation Factor IX (Human) Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Coagulation Factor IX (Human) Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Coagulation Factor IX (Human) Production, (2021-2026) & (K Pcs)
Table 46. Rest of World Based Manufacturers Coagulation Factor IX (Human) Production Market Share (2021-2026)
Table 47. World Coagulation Factor IX (Human) Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Coagulation Factor IX (Human) Production by Type (2021-2026) & (K Pcs)
Table 49. World Coagulation Factor IX (Human) Production by Type (2027-2032) & (K Pcs)
Table 50. World Coagulation Factor IX (Human) Production Value by Type (2021-2026) & (USD Million)
Table 51. World Coagulation Factor IX (Human) Production Value by Type (2027-2032) & (USD Million)
Table 52. World Coagulation Factor IX (Human) Average Price by Type (2021-2026) & (USD/Pcs)
Table 53. World Coagulation Factor IX (Human) Average Price by Type (2027-2032) & (USD/Pcs)
Table 54. World Coagulation Factor IX (Human) Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 55. World Coagulation Factor IX (Human) Production by Dosage Form (2021-2026) & (K Pcs)
Table 56. World Coagulation Factor IX (Human) Production by Dosage Form (2027-2032) & (K Pcs)
Table 57. World Coagulation Factor IX (Human) Production Value by Dosage Form (2021-2026) & (USD Million)
Table 58. World Coagulation Factor IX (Human) Production Value by Dosage Form (2027-2032) & (USD Million)
Table 59. World Coagulation Factor IX (Human) Average Price by Dosage Form (2021-2026) & (USD/Pcs)
Table 60. World Coagulation Factor IX (Human) Average Price by Dosage Form (2027-2032) & (USD/Pcs)
Table 61. World Coagulation Factor IX (Human) Production Value by Vial Strength, (USD Million), 2021 & 2025 & 2032
Table 62. World Coagulation Factor IX (Human) Production by Vial Strength (2021-2026) & (K Pcs)
Table 63. World Coagulation Factor IX (Human) Production by Vial Strength (2027-2032) & (K Pcs)
Table 64. World Coagulation Factor IX (Human) Production Value by Vial Strength (2021-2026) & (USD Million)
Table 65. World Coagulation Factor IX (Human) Production Value by Vial Strength (2027-2032) & (USD Million)
Table 66. World Coagulation Factor IX (Human) Average Price by Vial Strength (2021-2026) & (USD/Pcs)
Table 67. World Coagulation Factor IX (Human) Average Price by Vial Strength (2027-2032) & (USD/Pcs)
Table 68. World Coagulation Factor IX (Human) Production Value by Viral Safety Processing Route, (USD Million), 2021 & 2025 & 2032
Table 69. World Coagulation Factor IX (Human) Production by Viral Safety Processing Route (2021-2026) & (K Pcs)
Table 70. World Coagulation Factor IX (Human) Production by Viral Safety Processing Route (2027-2032) & (K Pcs)
Table 71. World Coagulation Factor IX (Human) Production Value by Viral Safety Processing Route (2021-2026) & (USD Million)
Table 72. World Coagulation Factor IX (Human) Production Value by Viral Safety Processing Route (2027-2032) & (USD Million)
Table 73. World Coagulation Factor IX (Human) Average Price by Viral Safety Processing Route (2021-2026) & (USD/Pcs)
Table 74. World Coagulation Factor IX (Human) Average Price by Viral Safety Processing Route (2027-2032) & (USD/Pcs)
Table 75. World Coagulation Factor IX (Human) Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 76. World Coagulation Factor IX (Human) Production by Application (2021-2026) & (K Pcs)
Table 77. World Coagulation Factor IX (Human) Production by Application (2027-2032) & (K Pcs)
Table 78. World Coagulation Factor IX (Human) Production Value by Application (2021-2026) & (USD Million)
Table 79. World Coagulation Factor IX (Human) Production Value by Application (2027-2032) & (USD Million)
Table 80. World Coagulation Factor IX (Human) Average Price by Application (2021-2026) & (USD/Pcs)
Table 81. World Coagulation Factor IX (Human) Average Price by Application (2027-2032) & (USD/Pcs)
Table 82. CSL Behring Basic Information, Manufacturing Base and Competitors
Table 83. CSL Behring Major Business
Table 84. CSL Behring Coagulation Factor IX (Human) Product and Services
Table 85. CSL Behring Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 86. CSL Behring Recent Developments/Updates
Table 87. CSL Behring Competitive Strengths & Weaknesses
Table 88. Takeda Basic Information, Manufacturing Base and Competitors
Table 89. Takeda Major Business
Table 90. Takeda Coagulation Factor IX (Human) Product and Services
Table 91. Takeda Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 92. Takeda Recent Developments/Updates
Table 93. Takeda Competitive Strengths & Weaknesses
Table 94. Grifols Biologicals Basic Information, Manufacturing Base and Competitors
Table 95. Grifols Biologicals Major Business
Table 96. Grifols Biologicals Coagulation Factor IX (Human) Product and Services
Table 97. Grifols Biologicals Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 98. Grifols Biologicals Recent Developments/Updates
Table 99. Grifols Biologicals Competitive Strengths & Weaknesses
Table 100. Octapharma Basic Information, Manufacturing Base and Competitors
Table 101. Octapharma Major Business
Table 102. Octapharma Coagulation Factor IX (Human) Product and Services
Table 103. Octapharma Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 104. Octapharma Recent Developments/Updates
Table 105. Octapharma Competitive Strengths & Weaknesses
Table 106. Kedrion Basic Information, Manufacturing Base and Competitors
Table 107. Kedrion Major Business
Table 108. Kedrion Coagulation Factor IX (Human) Product and Services
Table 109. Kedrion Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Kedrion Recent Developments/Updates
Table 111. Kedrion Competitive Strengths & Weaknesses
Table 112. Bio Products Laboratory Basic Information, Manufacturing Base and Competitors
Table 113. Bio Products Laboratory Major Business
Table 114. Bio Products Laboratory Coagulation Factor IX (Human) Product and Services
Table 115. Bio Products Laboratory Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 116. Bio Products Laboratory Recent Developments/Updates
Table 117. Bio Products Laboratory Competitive Strengths & Weaknesses
Table 118. LFB Basic Information, Manufacturing Base and Competitors
Table 119. LFB Major Business
Table 120. LFB Coagulation Factor IX (Human) Product and Services
Table 121. LFB Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 122. LFB Recent Developments/Updates
Table 123. LFB Competitive Strengths & Weaknesses
Table 124. Biotest Basic Information, Manufacturing Base and Competitors
Table 125. Biotest Major Business
Table 126. Biotest Coagulation Factor IX (Human) Product and Services
Table 127. Biotest Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 128. Biotest Recent Developments/Updates
Table 129. Biotest Competitive Strengths & Weaknesses
Table 130. KM Biologics Basic Information, Manufacturing Base and Competitors
Table 131. KM Biologics Major Business
Table 132. KM Biologics Coagulation Factor IX (Human) Product and Services
Table 133. KM Biologics Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 134. KM Biologics Recent Developments/Updates
Table 135. KM Biologics Competitive Strengths & Weaknesses
Table 136. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 137. Intas Pharmaceuticals Major Business
Table 138. Intas Pharmaceuticals Coagulation Factor IX (Human) Product and Services
Table 139. Intas Pharmaceuticals Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 140. Intas Pharmaceuticals Recent Developments/Updates
Table 141. Intas Pharmaceuticals Competitive Strengths & Weaknesses
Table 142. Shandong Taibang Biological Products Basic Information, Manufacturing Base and Competitors
Table 143. Shandong Taibang Biological Products Major Business
Table 144. Shandong Taibang Biological Products Coagulation Factor IX (Human) Product and Services
Table 145. Shandong Taibang Biological Products Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 146. Shandong Taibang Biological Products Recent Developments/Updates
Table 147. Shandong Taibang Biological Products Competitive Strengths & Weaknesses
Table 148. Sichuan Yuanda Shuyang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 149. Sichuan Yuanda Shuyang Pharmaceutical Major Business
Table 150. Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Product and Services
Table 151. Sichuan Yuanda Shuyang Pharmaceutical Coagulation Factor IX (Human) Production (K Pcs), Price (USD/Pcs), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 152. Sichuan Yuanda Shuyang Pharmaceutical Recent Developments/Updates
Table 153. Sichuan Yuanda Shuyang Pharmaceutical Competitive Strengths & Weaknesses
Table 154. Global Key Players of Coagulation Factor IX (Human) Upstream (Raw Materials)
Table 155. Global Coagulation Factor IX (Human) Typical Customers
Table 156. Coagulation Factor IX (Human) Typical Distributors
LIST OF FIGURES
Figure 1. Coagulation Factor IX (Human) Picture
Figure 2. World Coagulation Factor IX (Human) Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Coagulation Factor IX (Human) Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Coagulation Factor IX (Human) Production (2021-2032) & (K Pcs)
Figure 5. World Coagulation Factor IX (Human) Average Price (2021-2032) & (USD/Pcs)
Figure 6. World Coagulation Factor IX (Human) Production Value Market Share by Region (2021-2032)
Figure 7. World Coagulation Factor IX (Human) Production Market Share by Region (2021-2032)
Figure 8. North America Coagulation Factor IX (Human) Production (2021-2032) & (K Pcs)
Figure 9. Europe Coagulation Factor IX (Human) Production (2021-2032) & (K Pcs)
Figure 10. China Coagulation Factor IX (Human) Production (2021-2032) & (K Pcs)
Figure 11. Japan Coagulation Factor IX (Human) Production (2021-2032) & (K Pcs)
Figure 12. Coagulation Factor IX (Human) Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 15. World Coagulation Factor IX (Human) Consumption Market Share by Region (2021-2032)
Figure 16. United States Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 17. China Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 18. Europe Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 19. Japan Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 20. South Korea Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 21. ASEAN Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 22. India Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 23. Producer Shipments of Coagulation Factor IX (Human) by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Coagulation Factor IX (Human) Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Coagulation Factor IX (Human) Markets in 2025
Figure 26. United States VS China: Coagulation Factor IX (Human) Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Coagulation Factor IX (Human) Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Coagulation Factor IX (Human) Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Coagulation Factor IX (Human) Production Market Share 2025
Figure 30. China Based Manufacturers Coagulation Factor IX (Human) Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Coagulation Factor IX (Human) Production Market Share 2025
Figure 32. World Coagulation Factor IX (Human) Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Coagulation Factor IX (Human) Production Value Market Share by Type in 2025
Figure 34. High-Purity Coagulation Factor IX (Human)
Figure 35. Intermediate-Purity Coagulation Factor IX (Human)
Figure 36. Others
Figure 37. World Coagulation Factor IX (Human) Production Market Share by Type (2021-2032)
Figure 38. World Coagulation Factor IX (Human) Production Value Market Share by Type (2021-2032)
Figure 39. World Coagulation Factor IX (Human) Average Price by Type (2021-2032) & (USD/Pcs)
Figure 40. World Coagulation Factor IX (Human) Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 41. World Coagulation Factor IX (Human) Production Value Market Share by Dosage Form in 2025
Figure 42. Lyophilized Powder for Solution for Injection
Figure 43. Liquid Solution for Injection
Figure 44. Others
Figure 45. World Coagulation Factor IX (Human) Production Market Share by Dosage Form (2021-2032)
Figure 46. World Coagulation Factor IX (Human) Production Value Market Share by Dosage Form (2021-2032)
Figure 47. World Coagulation Factor IX (Human) Average Price by Dosage Form (2021-2032) & (USD/Pcs)
Figure 48. World Coagulation Factor IX (Human) Production Value by Vial Strength, (USD Million), 2021 & 2025 & 2032
Figure 49. World Coagulation Factor IX (Human) Production Value Market Share by Vial Strength in 2025
Figure 50. 250 IU and Below
Figure 51. Above 250 IU to 500 IU
Figure 52. Above 500 IU to 1000 IU
Figure 53. Above 1000 IU
Figure 54. World Coagulation Factor IX (Human) Production Market Share by Vial Strength (2021-2032)
Figure 55. World Coagulation Factor IX (Human) Production Value Market Share by Vial Strength (2021-2032)
Figure 56. World Coagulation Factor IX (Human) Average Price by Vial Strength (2021-2032) & (USD/Pcs)
Figure 57. World Coagulation Factor IX (Human) Production Value by Viral Safety Processing Route, (USD Million), 2021 & 2025 & 2032
Figure 58. World Coagulation Factor IX (Human) Production Value Market Share by Viral Safety Processing Route in 2025
Figure 59. Solvent-Detergent Treated Products
Figure 60. Virus-Filtered Products
Figure 61. Heat-Treated or Pasteurized Products
Figure 62. Multi-Step Viral Inactivation and Removal Products
Figure 63. World Coagulation Factor IX (Human) Production Market Share by Viral Safety Processing Route (2021-2032)
Figure 64. World Coagulation Factor IX (Human) Production Value Market Share by Viral Safety Processing Route (2021-2032)
Figure 65. World Coagulation Factor IX (Human) Average Price by Viral Safety Processing Route (2021-2032) & (USD/Pcs)
Figure 66. World Coagulation Factor IX (Human) Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 67. World Coagulation Factor IX (Human) Production Value Market Share by Application in 2025
Figure 68. Hospital
Figure 69. Personal Clinic
Figure 70. Others
Figure 71. World Coagulation Factor IX (Human) Production Market Share by Application (2021-2032)
Figure 72. World Coagulation Factor IX (Human) Production Value Market Share by Application (2021-2032)
Figure 73. World Coagulation Factor IX (Human) Average Price by Application (2021-2032) & (USD/Pcs)
Figure 74. Coagulation Factor IX (Human) Industry Chain
Figure 75. Coagulation Factor IX (Human) Procurement Model
Figure 76. Coagulation Factor IX (Human) Sales Model
Figure 77. Coagulation Factor IX (Human) Sales Channels, Direct Sales, and Distribution
Figure 78. Methodology
Figure 79. Research Process and Data Source
Figure 1. Coagulation Factor IX (Human) Picture
Figure 2. World Coagulation Factor IX (Human) Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Coagulation Factor IX (Human) Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Coagulation Factor IX (Human) Production (2021-2032) & (K Pcs)
Figure 5. World Coagulation Factor IX (Human) Average Price (2021-2032) & (USD/Pcs)
Figure 6. World Coagulation Factor IX (Human) Production Value Market Share by Region (2021-2032)
Figure 7. World Coagulation Factor IX (Human) Production Market Share by Region (2021-2032)
Figure 8. North America Coagulation Factor IX (Human) Production (2021-2032) & (K Pcs)
Figure 9. Europe Coagulation Factor IX (Human) Production (2021-2032) & (K Pcs)
Figure 10. China Coagulation Factor IX (Human) Production (2021-2032) & (K Pcs)
Figure 11. Japan Coagulation Factor IX (Human) Production (2021-2032) & (K Pcs)
Figure 12. Coagulation Factor IX (Human) Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 15. World Coagulation Factor IX (Human) Consumption Market Share by Region (2021-2032)
Figure 16. United States Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 17. China Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 18. Europe Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 19. Japan Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 20. South Korea Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 21. ASEAN Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 22. India Coagulation Factor IX (Human) Consumption (2021-2032) & (K Pcs)
Figure 23. Producer Shipments of Coagulation Factor IX (Human) by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Coagulation Factor IX (Human) Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Coagulation Factor IX (Human) Markets in 2025
Figure 26. United States VS China: Coagulation Factor IX (Human) Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Coagulation Factor IX (Human) Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Coagulation Factor IX (Human) Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Coagulation Factor IX (Human) Production Market Share 2025
Figure 30. China Based Manufacturers Coagulation Factor IX (Human) Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Coagulation Factor IX (Human) Production Market Share 2025
Figure 32. World Coagulation Factor IX (Human) Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Coagulation Factor IX (Human) Production Value Market Share by Type in 2025
Figure 34. High-Purity Coagulation Factor IX (Human)
Figure 35. Intermediate-Purity Coagulation Factor IX (Human)
Figure 36. Others
Figure 37. World Coagulation Factor IX (Human) Production Market Share by Type (2021-2032)
Figure 38. World Coagulation Factor IX (Human) Production Value Market Share by Type (2021-2032)
Figure 39. World Coagulation Factor IX (Human) Average Price by Type (2021-2032) & (USD/Pcs)
Figure 40. World Coagulation Factor IX (Human) Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 41. World Coagulation Factor IX (Human) Production Value Market Share by Dosage Form in 2025
Figure 42. Lyophilized Powder for Solution for Injection
Figure 43. Liquid Solution for Injection
Figure 44. Others
Figure 45. World Coagulation Factor IX (Human) Production Market Share by Dosage Form (2021-2032)
Figure 46. World Coagulation Factor IX (Human) Production Value Market Share by Dosage Form (2021-2032)
Figure 47. World Coagulation Factor IX (Human) Average Price by Dosage Form (2021-2032) & (USD/Pcs)
Figure 48. World Coagulation Factor IX (Human) Production Value by Vial Strength, (USD Million), 2021 & 2025 & 2032
Figure 49. World Coagulation Factor IX (Human) Production Value Market Share by Vial Strength in 2025
Figure 50. 250 IU and Below
Figure 51. Above 250 IU to 500 IU
Figure 52. Above 500 IU to 1000 IU
Figure 53. Above 1000 IU
Figure 54. World Coagulation Factor IX (Human) Production Market Share by Vial Strength (2021-2032)
Figure 55. World Coagulation Factor IX (Human) Production Value Market Share by Vial Strength (2021-2032)
Figure 56. World Coagulation Factor IX (Human) Average Price by Vial Strength (2021-2032) & (USD/Pcs)
Figure 57. World Coagulation Factor IX (Human) Production Value by Viral Safety Processing Route, (USD Million), 2021 & 2025 & 2032
Figure 58. World Coagulation Factor IX (Human) Production Value Market Share by Viral Safety Processing Route in 2025
Figure 59. Solvent-Detergent Treated Products
Figure 60. Virus-Filtered Products
Figure 61. Heat-Treated or Pasteurized Products
Figure 62. Multi-Step Viral Inactivation and Removal Products
Figure 63. World Coagulation Factor IX (Human) Production Market Share by Viral Safety Processing Route (2021-2032)
Figure 64. World Coagulation Factor IX (Human) Production Value Market Share by Viral Safety Processing Route (2021-2032)
Figure 65. World Coagulation Factor IX (Human) Average Price by Viral Safety Processing Route (2021-2032) & (USD/Pcs)
Figure 66. World Coagulation Factor IX (Human) Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 67. World Coagulation Factor IX (Human) Production Value Market Share by Application in 2025
Figure 68. Hospital
Figure 69. Personal Clinic
Figure 70. Others
Figure 71. World Coagulation Factor IX (Human) Production Market Share by Application (2021-2032)
Figure 72. World Coagulation Factor IX (Human) Production Value Market Share by Application (2021-2032)
Figure 73. World Coagulation Factor IX (Human) Average Price by Application (2021-2032) & (USD/Pcs)
Figure 74. Coagulation Factor IX (Human) Industry Chain
Figure 75. Coagulation Factor IX (Human) Procurement Model
Figure 76. Coagulation Factor IX (Human) Sales Model
Figure 77. Coagulation Factor IX (Human) Sales Channels, Direct Sales, and Distribution
Figure 78. Methodology
Figure 79. Research Process and Data Source
